Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis.
The new triazole, D0870, was tested for therapeutic efficacy in the treatment of experimental systemic murine coccidioidomycosis. D0870 at 1 or 10 mg kg-1 daily, or 10 or 100 mg kg-1 every other day, and fluconazole at 100 mg kg-1 daily prolonged survival (P < 0.01), but were equivalent to each other. D0870 at 10 mg kg-1 daily or 100 mg kg-1 every other day cured 20 or 30% of mice of residual infection, respectively, and were superior to 100 mg kg-1 of fluconazole daily (P < 0.001). D0870 is approximately 10-fold more active than fluconazole. It is a promising treatment for coccidioidomycosis, which warrants further testing.
Clemons
K V
KV
Dept. of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128-2699.
Stevens
D A
DA
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D003045:Coccidioides / Q000302:isolation & purification; D003047:Coccidioidomycosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D008099:Liver / Q000382:microbiology; D008168:Lung / Q000382:microbiology; D051379:Mice; D008815:Mice, Inbred Strains; D013154:Spleen / Q000382:microbiology; D013237:Stereoisomerism; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C058219:ICI 195739; D015725:Fluconazole